HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
RASA1
RAS p21 protein activator 1
Chromosome 5 Β· 5q14.3
NCBI Gene: 5921Ensembl: ENSG00000145715.16HGNC: HGNC:9871UniProt: P20936
271PubMed Papers
21Diseases
0Drugs
282Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub GeneTumor Suppressor
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
ephrin receptor signaling pathwayblood vessel morphogenesiscytoplasmprotein bindingcapillary malformation-arteriovenous malformation 1Capillary malformation - arteriovenous malformationcapillary malformation-arteriovenous malformation syndromebasal cell carcinoma
✦AI Summary

RASA1 encodes a GTPase-activating protein (GAP) that functions as a critical negative regulator of Ras signaling by facilitating the transition of Ras proteins from their active GTP-bound state to inactive GDP-bound state 1. The protein plays essential roles in vascular development, particularly in angiogenesis and lymphatic vessel formation. RASA1 physically interacts with EPHB4 to regulate lymphatic valve development by dampening Ras-MAPK activation induced through the PIEZO1 oscillatory shear stress sensor 2. This EPHB4-RASA1 signaling axis is crucial for proper cerebrovascular development and arteriovenous network formation 3. Loss-of-function mutations in RASA1 cause capillary malformation-arteriovenous malformation syndrome (CM-AVM), characterized by multifocal capillary malformations, arteriovenous malformations, and various lymphatic anomalies including pleural effusions, lymphatic malformations, and central conducting lymphatic anomalies 14. RASA1 mutations are also found in certain cancers, including lung adenocarcinomas and squamous cell carcinomas, where they contribute to tumor development through dysregulated Ras-MAPK signaling 56. The protein's dysfunction leads to abnormal angiogenic remodeling that cannot be compensated by other RasGAPs, highlighting its unique role in vascular biology 1.

Sources cited
1
RASA1 functions as a RasGAP that converts active GTP-bound Ras to inactive GDP-bound form and causes CM-AVM syndrome
PMID: 15917201
2
RASA1 physically interacts with EPHB4 to regulate lymphatic valve development by controlling Ras-MAPK activation through PIEZO1
PMID: 39421925
3
EphrinB2-EphB4-RASA1 signaling axis is important in cerebrovascular development
PMID: 30819650
4
RASA1 mutations cause CM-AVM with lymphatic anomalies including pleural effusions and lymphatic malformations
PMID: 37767822
5
RASA1 is a significantly mutated gene in lung squamous cell carcinoma
PMID: 27158780
6
RASA1 contributes to tumor formation through Ras/RAF/MEK/ERK signaling pathways
PMID: 33125148
Disease Associationsβ“˜21
capillary malformation-arteriovenous malformation 1Open Targets
0.83Strong
Capillary malformation - arteriovenous malformationOpen Targets
0.70Moderate
capillary malformation-arteriovenous malformation syndromeOpen Targets
0.65Moderate
basal cell carcinomaOpen Targets
0.64Moderate
Abnormality of the cardiovascular systemOpen Targets
0.54Moderate
angioosteohypertrophic syndromeOpen Targets
0.50Moderate
vascular malformationOpen Targets
0.49Moderate
squamous cell lung carcinomaOpen Targets
0.44Moderate
neurodegenerative diseaseOpen Targets
0.43Moderate
arteriovenous hemangioma/malformationOpen Targets
0.43Moderate
capillary malformationOpen Targets
0.37Weak
gastric carcinomaOpen Targets
0.37Weak
kidney neoplasmOpen Targets
0.37Weak
colorectal adenocarcinomaOpen Targets
0.37Weak
bile duct carcinomaOpen Targets
0.37Weak
carcinoma of liver and intrahepatic biliary tractOpen Targets
0.37Weak
Endometrial Endometrioid AdenocarcinomaOpen Targets
0.37Weak
Hepatobiliary NeoplasmOpen Targets
0.37Weak
Ovarian Endometrioid Adenocarcinoma with Squamous DifferentiationOpen Targets
0.37Weak
skin squamous cell carcinomaOpen Targets
0.37Weak
Capillary malformation-arteriovenous malformation 1UniProt
Pathogenic Variants282
NM_002890.3(RASA1):c.2125C>T (p.Arg709Ter)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome|Cardiovascular phenotype|Capillary malformation-arteriovenous malformation 1
β˜…β˜…β˜†β˜†2026β†’ Residue 709
NM_002890.3(RASA1):c.2698_2701del (p.Val900fs)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 900
NM_002890.3(RASA1):c.1733T>G (p.Leu578Ter)Pathogenic
Cardiovascular phenotype|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 578
NM_002890.3(RASA1):c.1579_1582del (p.Val527fs)Pathogenic
Capillary malformation-arteriovenous malformation syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 527
NM_002890.3(RASA1):c.383_384del (p.Leu128fs)Pathogenic
Capillary malformation-arteriovenous malformation syndrome|not provided|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 128
NM_002890.3(RASA1):c.2365C>T (p.Arg789Ter)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome|Vascular malformation|RASA1-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 789
NM_002890.3(RASA1):c.2422C>T (p.Gln808Ter)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 808
NM_002890.3(RASA1):c.2131C>T (p.Arg711Ter)Pathogenic
not provided|Basal cell carcinoma, susceptibility to, 1;Capillary malformation-arteriovenous malformation 1|Capillary malformation-arteriovenous malformation syndrome|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 711
NM_002890.3(RASA1):c.2149dup (p.Ile717fs)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 717
NM_002890.3(RASA1):c.1534C>T (p.Arg512Ter)Pathogenic
not specified|Capillary malformation-arteriovenous malformation syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 512
NM_002890.3(RASA1):c.2422_2423del (p.Gln808fs)Pathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome|Capillary malformation-arteriovenous malformation 1
β˜…β˜…β˜†β˜†2025β†’ Residue 808
NM_002890.3(RASA1):c.475_476del (p.Leu159fs)Pathogenic
Capillary malformation-arteriovenous malformation 1|not provided|Capillary malformation-arteriovenous malformation syndrome|Gorham-Stout disease
β˜…β˜…β˜†β˜†2025β†’ Residue 159
NM_002890.3(RASA1):c.611dup (p.Tyr204Ter)Pathogenic
Capillary malformation-arteriovenous malformation syndrome|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 204
NM_002890.3(RASA1):c.656C>G (p.Ser219Ter)Pathogenic
Capillary malformation-arteriovenous malformation 1;Basal cell carcinoma, susceptibility to, 1|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 219
NM_002890.3(RASA1):c.2603+1G>APathogenic
not provided|Capillary malformation-arteriovenous malformation syndrome|Capillary malformation-arteriovenous malformation 1
β˜…β˜…β˜†β˜†2025
NM_002890.3(RASA1):c.853C>T (p.Arg285Ter)Pathogenic
Capillary malformation-arteriovenous malformation 1|Capillary malformation-arteriovenous malformation syndrome|Vascular malformation|RASA1-related disorder|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 285
NM_002890.3(RASA1):c.2707C>T (p.Arg903Ter)Pathogenic
Capillary malformation-arteriovenous malformation 1|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 903
NM_002890.3(RASA1):c.1358_1359del (p.Thr453fs)Pathogenic
Capillary malformation-arteriovenous malformation syndrome|Capillary malformation-arteriovenous malformation 1|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 453
NM_002890.3(RASA1):c.13_37del (p.Glu5fs)Pathogenic
Capillary malformation-arteriovenous malformation 1|Capillary malformation-arteriovenous malformation syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 5
NM_002890.3(RASA1):c.1222C>T (p.Gln408Ter)Pathogenic
Capillary malformation-arteriovenous malformation syndrome|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 408
View on ClinVar β†—
Related Genes
TSC1Protein interaction100%ARHGAP35Protein interaction100%DOK1Protein interaction100%G3BP1Protein interaction99%ARF3Protein interaction99%RALAProtein interaction99%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
98%
Brain
87%
Heart
82%
Lung
62%
Liver
37%
Gene Interaction Network
Click a node to explore
RASA1TSC1ARHGAP35DOK1G3BP1ARF3RALA
PROTEIN STRUCTURE
Preparing viewer…
PDB2J05 Β· 1.50 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.30Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.21 [0.15–0.30]
RankingsWhere RASA1 stands among ~20K protein-coding genes
  • #1,360of 20,598
    Most Researched271 Β· top 10%
  • #220of 5,498
    Most Pathogenic Variants282 Β· top 5%
  • #1,140of 17,882
    Most Constrained (LOEUF)0.30 Β· top 10%
Genes detectedRASA1
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling.
PMID: 28687708
Circulation Β· 2017
1.00
2
EphrinB2-EphB4-RASA1 Signaling in Human Cerebrovascular Development and Disease.
PMID: 30819650
Trends Mol Med Β· 2019
0.90
3
Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-ΞΊB, and Up-regulating Expression of MicroRNA-21.
PMID: 27876571
Gastroenterology Β· 2017
0.80
4
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
PMID: 27158780
Nat Genet Β· 2016
0.80
5
The genetics of vascular birthmarks.
PMID: 35181412
Clin Dermatol Β· 2022
0.72